Results 61 to 70 of about 2,650 (185)

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients

International Journal of Retina and Vitreous, 2022
Background The current standard treatment for neovascular age-related macular degeneration (nAMD) involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents.
Sanjay Kumar Mishra, Pradeep Kumar, Srishti Khullar, Amrita Joshi, Alok Sati, Sonali Vinay Kumar, Deepesh Unni, Atul Kumar   +7 more
doaj   +1 more source

Dual acting therapeutic proteins for intraocular use [PDF]

, 2020
Antibody-based medicines that target vascular endothelial growth factor (VEGF) are administered by intravitreal injection to treat chronic neovascular retinal diseases.
Awwad, S., Awwad, S., Brocchini, S., Brocchini, S., Collins, M., Collins, M., Guiliano, D., Guiliano, D., Ibeanu, N., Ibeanu, N., Khalili, H., Khalili, H., Khaw, P. T., Khaw, P. T.   +13 more
core   +1 more source

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1156-1167, December 2025.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies   +9 more
wiley   +1 more source

Functional and anatomical outcomes of brolucizumab for nAMD in a real-life setting [PDF]

To report long-term outcomes of brolucizumab in neovascular age-related macular degeneration (nAMD) treatment. Records from 74 patients were retrospectively reviewed. Both naïve eyes and those previously treated with other antiVEGF agents were included.
Cirigliano, Gabriella, Milan, Serena, Pastore, Marco Rocco, Tognetto, Daniele   +3 more
core   +1 more source

Recurrent Anterior Chamber Migration of Intravitreal Triamcinolone Following Scleral‐Fixated IOL Implantation

Clinical Case Reports, Volume 13, Issue 11, November 2025.
ABSTRACT In eyes with a scleral‐fixated IOL, intravitreal triamcinolone may migrate into the anterior chamber, resulting in early‐onset elevation of IOP, even at small volumes. Prompt slit lamp and gonioscopic evaluation is recommended for patients with prior vitrectomy or posterior capsule defects to ensure timely detection and treatment.
Yuki Takagi, Sho Yokoyama, Kazunori Takeuchi   +2 more
wiley   +1 more source

Intravitreal Therapy for Diabetic Macular Edema: An Update [PDF]

, 2021
Diabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-Threatening condition, it is also among the most accessible to treatment.
Alessio G., Boscia F., Furino C., Reibaldi M.   +3 more
core   +1 more source

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration

Advanced Science, Volume 12, Issue 39, October 20, 2025.
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz, Jessica Cutrufello, Michael Lam, Shreya Nallaparaju, Nicholas A. Peppas   +4 more
wiley   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source